Atreca holds off development on its only clinical program, cuts headcount by 40%

In a bid to extend its cash runway, Atreca has suspended the clinical development of its solid tumor monoclonal antibody ATRC-101, slashing staff numbers by 40%. The company will focus on its preclinical antibody-drug conjugate (ADC) assets instead.

The San Carlos, CA biotech’s Phase Ib ATRC-101 was the most advanced candidate in its six-asset pipeline, three of which are ADCs. One of its ADCs will be selected as a clinical candidate in the coming months, with a possible IND submission late next year at the earliest.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。